Powered by RND
PodcastsSaúde e fitnessDiabetes Connections | Type 1 Diabetes

Diabetes Connections | Type 1 Diabetes

Stacey Simms
Diabetes Connections | Type 1 Diabetes
Último episódio

Episódios Disponíveis

5 de 731
  • What’s ahead for Tandem Diabetes? An update on pumps, CGMs, infusion sets, and more!
    This week on Diabetes Connections, Tandem Diabetes made some big announcements at the recent ADA Conference – we’re going behind the headlines and asking your questions about Control IQ updates, extended wear infusion sets, what’s happening with their patch pumps, and a lot more. I’m talking to Ben Mar the Director of Product marketing. We also getting into their expanded partnership with Abbott – in additional to the Libre 3 plus, they’re one of the pump companies that has signed on for the future glucose/ketone sensor. A lot to get to here! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Previous episodes with Ben Mar here Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.
    --------  
    39:45
  • In the News...Top Stories from ADA and more!
    It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: loads of news from American Diabetes Association Scientific Sessions, GLP1 for T1D, Tech updates, diabetes in space, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: [email protected] Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Top story – looking back at The American Diabetes Association Scientific Sessions conference. I won’t recap everything here – but I’ll link up to a few more comprehensive article. Here’s just a taste! XX A single infusion of a new stem cell-based treatment helped 10 out of 12 people with severe type 1 diabetes stop using insulin, researchers report. The treatment, called zimislecel, was made by Vertex Pharmaceuticals. It’s an infusion of lab-grown islet cells. A year after getting the therapy, 10 patients no longer needed insulin shots. The other two were able to reduce how much insulin they needed.  The treatment requires patients to take immunosuppressive drugs, which may raise the risk of infections or cancer in the long run, experts said. https://www.usnews.com/news/health-news/articles/2025-06-24/stem-cell-treatment-may-free-some-with-type-1-diabetes-from-insulin XX New study shows inhaled insulin is safe and effective for children with type 1 diabetes. This is Mannkind’s Afrezza, which takes the place of rapid-acting mealtime insulin. Findings indicate that inhaled insulin delivers glycemic control comparable to injected rapid-acting insulin. Inhaled insulin was also associated with less weight gain and slightly higher patient and parent preference scores. These findings add to outcomes shared from INHALE 1 late last year. Based on the findings of the inhaled insulin study, MannKind looks to seek FDA approval to expand Afrezza’s indication to children. The company also aims to evaluate inhaled insulin at diagnosis and in automated insulin delivery systems in additional studies. https://www.drugdeliverybusiness.com/study-mannkind-inhaled-insulin-safe-effective-children/ XX Positive outcomes in two different studies looking at GLP 1 medications for type 1. Semaglutide – brand name Ozempic or Wegovy - reduced glucose levels and weight among patients with type 1 diabetes and obesity. 26-week, double-blind trial of 72 adults, those taking Ozempic spent More than 70% time spent in sensor glucose range (70-180 mg/dL) Less than 4% time spent in hypoglycemia ( At least 5% body weight reduction Although none of the GLP-1 receptor agonists are approved for type 1 diabetes -- largely due to safety concerns about hypoglycemia and diabetic ketoacidosis -- Shah pointed to real-world dataopens in a new tab or window that showed increasing off-label use in this population. Half of the patients in the semaglutide group achieved an HbA1c level below 7% at 26 weeks compared with 22.2% of those in the placebo group. Semaglutide patients also had greater weight loss (least-squares mean group difference -8.8 kg [19.4 lb]). As for adverse events of special interest for a type 1 diabetes population, rates of severe hypoglycemia were low (5.5% vs 5.5%) and no cases of diabetic ketoacidosis occurred. https://www.medpagetoday.com/meetingcoverage/ada/116206 XX   Tirzepatide – brand name Monjourno or Zepbound has demonstrated promising safety and efficacy in people with type 1 diabetes (T1D) in new data from a longitudinal, retrospective study.1 after 3 months, participants experienced a significant 6.7 kg reduction in mean weight (95% CI, 5.4-8.0 kg; P P P = .001; n=26.) Furthermore, time in range (70-180 mg/dl) also significantly increased from 54.9% to 60.8% (95% CI, 0.0-11.8; P = .048l; n = 36).1 “In people with T1D and obesity, there's quite a lot of off label GLP-1 agonist use and tirzepatide, as a proportion of that, is increasing,” Berry told HCPLive. “People found it really beneficial, but I would caution that it's retrospective data and randomized control trials are needed to confirm those benefits that we found. https://www.hcplive.com/view/off-label-tirzepatide-early-promise-type-1-diabetes-berry XX Looking ahead, though, a daily pill looks to be about as effective as a weekly Ozempic injection at inducing weight loss and lowering blood sugar. This is orforglipron. Like other GLP-1 medications, it mimics a hormone that regulates blood sugar and curbs appetite.  Long way to go here for approval, but this and many other medications, are being raced to market to try to catch up with the established medications.. it’s thought one in 8 americans are now taking a GLP 1 https://www.nytimes.com/2025/06/21/well/new-weight-loss-drugs.html XX Sequel Med Tech has a launch date for its twiist system – coming up quick, July 7th. The twist uses Tidepool loop software Sequel announced in March that it agreed with Abbott to make the Libre system its first continuous glucose monitor (CGM) integration for twiist. The company also recently struck an agreement with Abbott to integrate with a future dual glucose-ketone sensor and has a deal to integrate the pump with the Senseonics Eversense 365 year-long implantable CGM. https://www.drugdeliverybusiness.com/sequel-launch-twiist-aid-system-july/ XX Medronic spins off ti’s diabetes business, which will now be called Minimed. At ADA they showed off their next tubed pump, the MiniMed 8-series, which is about half the size of its current 780G pump, has no screen and is controlled by a phone.   Medtronic also showcased a patch pump in development. It  has a semi-durable design with a rechargeable battery, a larger insulin reservoir, at 300 units, and a longer wear time, at seven days. No timeline for that, but likely not before 2027, Beta Bionics also showed a prototype for their new patch pump – they’re calling it Mint. This is also a mix of disposable and reusable components, last three days and take up to 200 units of insulin. You’ll hear from Tandem in our next episode, out this Tuesday.. they’re working on a tubeless option for its smaller Mobi insulin pumps and a separate patch pump called Sigi, which will be rechargeable and come with pre-filled insulin cartridges. The slim x3 is still also in the works. -- On the CGM front.. Abbot has signed deals for their future sensor that can detect glucose and ketones.  They’re partnering with Tandem, Sequel and Beta Bionics so far. -- Dexcom is also working on monitoring ketones.. that will likely happen with the G8, now in trials. -- The Eversense CGM in the mix, showing off the plans they shared with us just a couple of weeks ago. Right now the Eversnese can stay on for a year.. next up is Gemini which is fully implantable – so no charging - but still needs a transmitter on top. Further out is Freedom, which would do away with the transmitter on top of the skin. https://www.medtechdive.com/news/ada-conference-diabetes-new-pumps-cgms/751482/ XX Once weekly basal insulin looks just as safe as daily basal in people with type 2. This is Lilly’s efsitora insulin..  Novo Nordisk, has received approval for use in adults with diabetes by the European Union and by Canada. Both companies hope to get approval in the US.         https://www.medscape.com/viewarticle/once-weekly-efsitora-noninferior-daily-insulin-t2d-2025a1000gm1 XX XX Dexcom announces what it calls enhancements to event logging. You can add a photo to your meals and AI will populate meal descriptions. It won’t carb count, but it will identify the food. I’ve seen some demonstrations of this and it seems to work pretty well. You can log exercise as well and see how the food and activity will impact blood sugar. I can’t wait to ask Dexcom about this – I’ve got to believe their using all the data to work on a carb counting AI app here – where you’d just a take a photo and get the carb count OR you’d just take a photo and an AID system would know what to do.. that’s my speculation. XX An American Diabetes Association expert panel that Cusi helped lead recently published a consensus report that urges physicians to screen people with Type 2 diabetes or prediabetes for a liver disease triggered by accumulated fat in the organ.   The condition — metabolic dysfunction-associated steatotic disease, or MASLD — often has no early symptoms but can progress to cirrhosis, liver failure and liver cancer without early diagnosis and intervention. The disorder, which can occur in those with or without diabetes, was previously known as nonalcoholic fatty liver disease.   Liver screening is especially urgent, the report said, especially for those who have obesity and Type 2 diabetes. Some individuals with Type 1 diabetes who have obesity are also at risk.   Early intervention, however, can reduce and even reverse the risk. Interventions include lifestyle and dietary changes, weight management and glucose-lowering medications. https://ufhealth.org/news/2025/new-report-recommends-liver-screening-for-those-with-type-2-diabetes XX   XX Axiom Mission 4 (Ax-4), which lifted off from Kennedy Space Center in Florida this week. One of the mission’s most significant research initiatives, Suite Ride, is a collaboration between Abu Dhabi-headquartered Burjeel Holdings and Axiom Space, with the potential to transform the future of space travel for astronauts with insulin-dependent diabetes mellitus (IDDM), a condition historically considered disqualifying for space missions. The Suite Ride study will utilise Continuous Glucose Monitors (CGMs), which have become the standard for glucose monitoring in individuals with diabetes. These devices will be tested to ensure their accuracy in microgravity, providing real-time data that will ultimately support the health of astronauts with IDDM. The comprehensive preflight, inflight and postflight protocols will employ various testing methods to validate these technologies. The Ax-4 mission plans to look at insulin exposure in microgravity to assess the potency and stability of the drug product upon its return to Earth. https://gulfnews.com/uae/uae-led-diabetes-research-takes-off-to-space-on-axiom-mission-4-1.500176357
    --------  
    7:48
  • Still Not Waiting: Lane Desborough's Bold New Push with Nudge
    This week on Diabetes Connections, “We are not waiting” became more than just a slogan — it sparked a movement. Back when the diabetes community was fed up with slow progress, DIYers stepped in with solutions that actually worked better than what companies were offering. That rallying cry? It came from Lane Desborough in 2013. And more than a decade later, he’s still challenging the status quo. We’re catching up with Lane to talk about his latest project, Nudge — much more than just another insulin pump algorithm, it’s an innovation to create more open and accessible systems This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.
    --------  
    1:00:02
  • Cloak the Poke: A New Way to Make Shots Less Scary
    As we gear up for ADA Scientific Sessions and get ready to hear studies and reports from the big diabetes companies, I’ve decided to highlight something on the other end of the spectrum. College students, seeing a need and developing a solution. Cloak The Poke is all about addressing fear of needles, especially in kids. We’ll explain how it works,  more about the team behind it, and their big goals going forward. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Cloak the Poke Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.
    --------  
    26:55
  • In the News... Omnipod updates, Tandem + Abbott, Dr. Pepper Zero recall, American Ninja and more!
    It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: what is adaptive biobehavioral control for AID systems? Omnipod 5 launches iOS app with Dexcom G7 compatability and a comic book(?!), Tandem and Abbott announce new partnership, Katie Bone is back on American Ninja Warrior, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: [email protected] Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX The American Diabetes Association Scientific Sessions kicks off in a week – we expect as always to get a lot of information! I’m not covering in person this year, but I’ll bring you any big announcements. And we’ll do a wrap up In the News the following week. -- XX UVA with something new.. technology that allows an artificial pancreas system to adapt to users’ changing needs – and lets users adjust the settings – beyond what’s commercially available now. They’re calling this “adaptive biobehavioral control,” the technology helps fine-tune UVA’s artificial pancreas every two weeks, giving users a virtual tool to test different ways to manage their blood sugar using their own data. In a six-month study, participants using the technology spent more time in a healthy blood-sugar range, rising from 72% to 77%, and saw a small but meaningful drop in their average blood-sugar levels. While automated insulin delivery systems help users better manage Type 1 diabetes, adaptive biobehavioral control technology is designed to improve blood-sugar control during the day, when fluctuations occur more frequently due to meals and physical activity. This new technology uses “digital twins,” computer models simulating how a person’s body processes sugar. The models help the artificial pancreas keep up with changes in the user’s body and habits and give users a way to interact with the system. For example, users can try different settings, like how much insulin is released overnight, using the simulation before applying them in real life. https://news.virginia.edu/content/uvas-artificial-pancreas-uses-digital-twin-tech-improve-diabetes-control XX Five years later after COVID-19 his the US, a new study shows that there is a connection with type 1 diabetes triggers. This is  new research from the University of Utah published in the journal ImmunoInformatics.   With T1D in particular, a COVID infection appears to trigger the immune system of certain people who have a prior susceptibility to the condition to subsequently develop T1D symptoms, the new study suggests.   University of Utah researchers hypothesize that COVID is leading to T1D diagnoses in a roundabout way as the virus presents the body with “molecular mimics,” or fragments of COVID proteins that bear an uncanny resemblance to those beta cell antigens.   When a person is infected with COVID, the immune system not only attacks fragments of the viral protein but also attacks fragments of beta cell antigens because they look so similar and get mistaken for each other, explains lead study author Julio Facelli, Ph.D., a distinguished professor of biomedical informatics at University of Utah Health in Salt Lake City. That means that in people who are already predisposed to T1D, there may be a simultaneous autoimmune reaction involving the destruction of healthy beta cells, spurring the onset of type 1 diabetes. Both 2022 and 2024 research indicates that there has been a significant increase in new onset type 1 diabetes following the start of the COVID pandemic. It’s difficult to estimate just how many cases may have been triggered by COVID because numerous viruses, including rotavirus, measles, mumps, and rubella, can spark an autoimmune response that activates T1D, according to the 2022 research published in Immunology & Cell Biology.   Again, it’s important to note that researchers don’t believe a COVID infection is causing diabetes, but rather, triggering it, in the same way certain environmental factors are believed to trigger immune-mediated conditions like Crohn’s and psoriasis. “   https://www.healthcentral.com/news/type-1-diabetes/how-covid-might-trigger-t1d XX Insulet announces the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7. Eric Benjamin, Insulet Executive Vice President, Chief Product and Customer Experience Officer. “With the addition of the Dexcom G7 sensor to the Omnipod 5 App for iPhone, our U.S. customers have more choice with fewer devices to keep track of, making it easier than ever to manage their diabetes.” The Omnipod 5 App with Dexcom G7 and Dexcom G6 compatibility is now available for download on the Apple App Store. Switching to a new Omnipod 5 device will require you to go through First Time Setup again. Insulin delivery history from previous Pods will be lost when you switch to your new device and adaptivity will start over. Use this guide and video to help transfer your settings: Omnipod also announced a collaboration with Marvel.. on an original comic to celebrate representation for the diabetes community and empower people with diabetes to unleash their inner hero. “Dyasonic: Sound of Strength” features Omnya, who was recently diagnosed with type 1 diabetes, struggles with her management, and is prescribed an insulin pump. Omnya learns that when her glucose levels are in range she can take on anything, and anyone, and transforms into the comic’s hero, Dyasonic! The hope is that readers will be able to see themselves overcoming these same challenges and break mental barriers to adopting technology with the potential for improved outcomes and quality of life. D’Spayre is a Marvel villain who preys on victims who are in despair, using their fear to strengthen himself—akin to the negative emotions that can come with diabetes. Insulet remains dedicated to advancing diabetes technology and improving the lives of people with diabetes. For more information, please visit https://www.omnipod.com/innovation. XX Tandem is the latest partner for Abbot’s future Glucose-Ketone Sensor. New agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis. Sequel Med Tech is also partnering with Abbott on this, as part of the twist pump, launching later this year. https://www.stocktitan.net/news/TNDM/tandem-diabetes-care-announces-agreement-with-abbott-for-integration-xl1vug3c0axy.html   XX New guidelines for the management of type 2 diabetes and prediabetes include tools clinicians can use to help patients stick to lifestyle interventions.   A panel of practitioners working in lifestyle medicine, including primary care physicians, cardiologists, endocrinologists, sleep experts, dietitians, and exercise medicine specialists, laid out six areas clinicians should help patients manage. These include sleep and stress, nutrition, physical activity, tobacco and alcohol, and social connection. The guidelines, released on June 10 by the American College of Lifestyle Medicine (ACLM), largely mirror lifestyle guidelines by the American Diabetes Association (ADA) but add specifics about how clinicians can help patients achieve their goals. Each patient should still receive tailored counseling, which may include medication   https://www.medscape.com/viewarticle/new-guidelines-shift-diabetes-care-toward-behavior-2025a1000fht XX Microplastics from a widely used biodegradable material can enter the metabolic cycle of bacteria and cells in the gut after being ingested, a new study has found. Researchers in China and the United States said the microplastics – from polylactic acid – were found to alter the gut metabolism and damage the gut barrier of mice.   They said this could potentially contribute to conditions like inflammatory bowel disease and diabetes. In recent years, microplastics have been found in human lungs, kidneys, blood, placenta and breast milk.   https://www.scmp.com/news/china/science/article/3313412/microplastics-biodegradable-material-may-be-linked-diabetes-study-finds XX ​​Over 19,000 cases of Dr Pepper Zero Sugar are being recalled after the cans were found to contain full-sugar soda, the U.S. Food and Drug Administration announced. The voluntary recall, initiated May 23, affects 12-pack and 24-pack cases of the 12-ounce aluminum cans that are labeled “Dr Pepper Zero Sugar.” Despite the label, the drinks inside contain the same amount of sugar found in regular Dr Pepper — about 39 grams per can — posing a health risk for people with diabetes or anyone needing to limit sugar intake. On Thursday, June 5, the FDA officially classified the recall as Class II, meaning the product “may cause temporary or medically reversible adverse health consequences." DR PEPPER ZERO SUGAR - 12 OZ, 12 PK DR PEPPER ZERO SUGAR - 12 OZ, 12 PK.  Amazon Consumers can identify the recalled cases by the product code, which is listed as  XXXXRS05165, and the "best by" date of Feb. 16, 2026   No other Dr Pepper products or batches of Dr Pepper Zero Sugar are part of the recall. https://people.com/dr-pepper-recall-sugar-found-in-zero-sugar-cans-11750981     XX A step forward for a device that uses breath to gather information about blood sugar. It’s called Isaac, the company is PreEvnt, you wear it on a lanyard and breathe into it. The breathalyzer technology was developed in collaboration with the Integrated Nanosystems Development Institute at IU Indianapolis, and was inspired by diabetes alert dogs. "Our lab was able to successfully identify the specific molecules in breath that correlate with hypoglycemia, which is the 'scent' that diabetic alert dogs can detect," said Mangilal Agarwal, director of the Integrated Nanosystems Development Institute and a professor in the IU Luddy School of Informatics, Computing and Engineering at IU Indianapolis. Agarwal's lab is partnering with the IU School of Medicine to test and validate the effectiveness of the device in individuals with diabetes—an important next step on the path to wider commercialization. https://medicalxpress.com/news/2025-06-breathalyzer-device-diabetes.html#google_vignette XX Katie Bone is back on American Ninja Warrior! The youngest ever American Ninja Warrior Women’s National winner, she injured her knee at Olympic Climbing Trials in 2023. This week, she was back on the show. She says: Katie Bone: It was incredible. I’ve not been able to compete for a few years, so getting to come back and hit a buzzer on my first chance back on the course felt really, really incredible; Very rewarding after everything I had to go through to get back there. XX  
    --------  
    8:23

Mais podcasts de Saúde e fitness

Sobre Diabetes Connections | Type 1 Diabetes

The T1D news show you've been waiting for! Long-time broadcaster, blogger and diabetes mom Stacey Simms interviews prominent advocates, authors and speakers. Stacey asks hard questions of healthcare companies and tech developers and brings on "everyday' people living with type 1. Great for parents of T1D kids, adults with type 1 and anyone who loves a person with diabetes.
Sítio Web de podcast

Ouve Diabetes Connections | Type 1 Diabetes, A Invenção do Amor e muitos outros podcasts de todo o mundo com a aplicação radio.pt

Obtenha a aplicação gratuita radio.pt

  • Guardar rádios e podcasts favoritos
  • Transmissão via Wi-Fi ou Bluetooth
  • Carplay & Android Audo compatìvel
  • E ainda mais funções
Aplicações
Social
v7.20.1 | © 2007-2025 radio.de GmbH
Generated: 7/4/2025 - 4:14:43 AM